ADAP - Adaptimmune: Clear Leader In TCR Therapies Targeting Solid Tumors Speculative Investment
- Immense potential, TCR therapy leader, but early stage.
- Science looks excellent with some proof of concept but risks, especially toxicity risks, abound.
- If successful, this could be a killer investment. If not, you will lose your entire money.
For further details see:
Adaptimmune: Clear Leader In TCR Therapies Targeting Solid Tumors, Speculative Investment